5 Drug Hopefuls That Are Going to Change Your Life: Part 3

By Sean Williams Every year, the promise of safer and more effective drugs coming to market gives an aging population hope. According to the Phrma organization’s website, roughly ...

Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint

New Data Presented at American Society of Hematology Annual Meeting Show Activity Against Disease and Symptom Alleviation By Sanofi  PARIS, Dec. 9, 2012 /PRNewswire/ — Sanofi ...

Don’t Be Surprised If Underpriced Small-Cap Biotechs Catch Investors’ Eye Once Again

By Gene Marcial Biotechnology stocks haven’t produced much excitement for investors this year , partly because the Presidential elections and national politics usurped much of the ...

ARIAD Announces 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Chronic-Phase CML Patients

56 percent major cytogenetic response and 34 percent major molecular response reported By ARIAD Pharmaceuticals, Inc. ATLANTA, & CAMBRIDGE, Mass.–(BUSINESS WIRE)–  ARIAD ...

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies from Multiple Presentations at ASH Annual Meeting

-34 Percent Objective Response Rate in Phase II Trial for Relapsed or Refractory Non-Hodgkin Lymphomas, Including 44 Percent in Diffuse Large B-cell Lymphoma (DLBCL)- -Long-term Follow-up ...

The Worst-Performing Biotechs in 2012 and 1 to Avoid in 2013

By Sean Williams As we enter the final few weeks of 2012, I thought it would be a positive reflective activity to look at the worst biotech performers in 2012, examine why that had ...

Gilead Sciences Leads The Race In Developing A Hepatitis C Pill

By Peter Geschek The race to develop a hepatitis C pill is one of the most dramatic in the pharmaceutical industry. Almost no month goes by without surprises, good as well as bad. Incivek from Vertex ...

Pharmacyclics Blood-Cancer Drug Controls Disease in Study

By Ryan Flinn Pharmacyclics Inc. (PCYC)’s experimental treatment for chronic lymphocytic leukemia, a blood cancer that affects adults 50 and older, slowed progression of the disease ...

Invest in the Great Progress of Hepatitis C

By George S. Mack of The Life Sciences Report. For more interviews with sector experts and analysts, please sign up for our newsletter atwww.thelifesciencesreport.com. There are a ...

Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemoglobinopathies at 54th American Society of Hematology (ASH) Annual Meeting

– ALN-TMP, an RNAi Therapeutic Targeting Tmprss6 for the Treatment of Hemoglobinopathies, Shows Disease Modifying Effects in Model of β-Thalassemia including Correction of Globin ...

Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera

Filing Triggered a $4 Million Milestone Payment to Halozyme From Roche Data From Subcutaneous MabThera Trials Presented at the American Society of Hematology Annual Meeting By Halozyme ...

AbbVie’s Life After Abbott

By Keith Speights We are just weeks away from the debut of a brand new company on the market. Actually, the brand will be new, but the company itself will bring lots of history with ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS